LIVIVO - Search results -

Search results

Result 1 - 10 of total 27

Search options

Article: EBV Negative Angioimmunoblastic T-Cell Lymphoma with Sequential Development of Diffuse Large B-Cell Lymphoma in Course of Progression.

Petković, Ivan / Stojnev, Slavica / Popović, Aleksandar / Krstić, Miljan / Pejčić, Ivica

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion

2021 Volume 37, Issue 4, Page(s) 694–696

Language	English
Publishing date	2021-03-25
Publishing country	India
Document type	Journal Article
ZDB-ID	2422370-0
ISSN	0974-0449 ; 0971-4502
ISSN (online)	0974-0449
ISSN	0971-4502
DOI	10.1007/s12288-021-01425-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- Full text online
- Order with fees

Article ; Online: Single Center Experience Study with Pembrolizumab in Patients with BRAF Mutant Negative Metastatic Melanoma

Pejčić Ivica / Petković Ivan / Cvetanović Ana / Conić Irena

Acta Facultatis Medicae Naissensis, Vol 35, Iss 4, Pp 267-

2018 Volume 272

Abstract: The aim of the paper was to determine the efficacy, toxicity and progression free survival with anti-PD-1 immunotherapy pembrolizumab in BRAF wild type metastatic melanoma patients with good performance status (ECOG PS 0-1). From February 2017 to April ... ...

Abstract	The aim of the paper was to determine the efficacy, toxicity and progression free survival with anti-PD-1 immunotherapy pembrolizumab in BRAF wild type metastatic melanoma patients with good performance status (ECOG PS 0-1). From February 2017 to April 2018, 17 patients with BRAF mutant wild type metastatic melanoma were enrolled in the study. Only 3/17 patient had received chemotherapy previously. The aim of the study was to confirm the efficacy of pembrolizumab immunotherapy in patients with good performance status (ECOG 0-1). Treatment consisted of pembrolizumab 2 mg/kg Q3 weeks continued until disease progression or intolerable toxicity. Secondary end points included toxicity and progression-free survival (defined as the time from randomization to documented disease progression according to RECIST). The overall response rate (ORR) was 11/17 (53.0 %), with complete response (CR) 0, partial response (PR) 3 (18 %), stable disease (SD) 8 (47%), and progressive disease (PD) 6 (35%). A total number of 97 consecutive cycles were administered. Adverse effects were mild. The most common toxicity was pneumonitis grade 1. None of the patients in the study demonstrated grade 2, 3 and 4 toxicity. No treatment-related deaths occurred. The median time to disease progression was 5.8 months. Anti-PD-1 pembrolizumab immunotherapy appeared to be a beneficial therapeutic approach with less toxicity for metastatic BRAF wild type melanoma patients with good PS.
Keywords	immunotherapy ; pembrolizumab ; metastatic melanoma ; Medicine ; R
Subject code	610
Language	English
Publishing date	2018-12-01T00:00:00Z
Publisher	Sciendo
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Current and future targets and therapies in metastatic colorectal cancer.

Dzunic, Miljana / Petkovic, Ivan / Cvetanovic, Ana / Vrbic, Svetislav / Pejcic, Ivica

Journal of B.U.ON. : official journal of the Balkan Union of Oncology

2019 Volume 24, Issue 5, Page(s) 1785–1792

Abstract: Colorectal cancer (CRC) is the third most common cancer and the second cause of cancer-related deaths worldwide. Despite early diagnosis and treatment improvement, the majority of patients will still suffer from metastatic disease (mCRC), which has a ... ...

Abstract	Colorectal cancer (CRC) is the third most common cancer and the second cause of cancer-related deaths worldwide. Despite early diagnosis and treatment improvement, the majority of patients will still suffer from metastatic disease (mCRC), which has a poor prognosis. Molecular diversity of CRC requires personalized targeted approach for improving patient outcomes. Antiangiogenic agents proved to be beneficial in the continuum of mCRC treatment. For efficient epidermal growth factor receptor (EGFR) directed therapy, subtle molecular selection and better strategies to overcome resistance are needed. BRAF mutant and HER-2 positive mCRC will soon be provided with approved targeted treatments and check-point inhibitors demonstrated effectiveness in microsatellite instability (MSI) - high mCRC. Moreover, numeorous promising agents are entering clinical trial arena. This review summarizes actual and possible targets and current and promising agents for mCRC treatment. With broader accessibility of liquid biopsy we could track molecular evolution of CRC and target genetic alterations as they emerge.
MeSH term(s)	Animals ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/metabolism ; Colorectal Neoplasms/pathology ; Drug Design ; Drug Resistance, Neoplasm ; Gene Expression Regulation, Neoplastic ; Humans ; Molecular Targeted Therapy ; Neoplasm Metastasis ; Signal Transduction
Chemical Substances	Antineoplastic Agents ; Biomarkers, Tumor
Language	English
Publishing date	2019-11-30
Publishing country	Greece
Document type	Journal Article ; Review
ZDB-ID	2040386-0
ISSN	2241-6293 ; 1107-0625
ISSN (online)	2241-6293
ISSN	1107-0625
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5438: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Proteasome inhibitors

Petković Ivan / Pejčić Ivica / Vrbić Svetislav

Racionalna Terapija, Vol 8, Iss 2, Pp 25-

A rational for clinical use in the treatment of multiple myeloma

2016 Volume 33

Abstract: Proteasome inhibitors (PI) represent the class of medicaments which lead to inhibition of catalytic chymotrypsin-like proteolytic proteasome subunits. Blockade of this specific structure drives to complete ubiquitin-proteasome machinery withdrawal. Total ...

Abstract	Proteasome inhibitors (PI) represent the class of medicaments which lead to inhibition of catalytic chymotrypsin-like proteolytic proteasome subunits. Blockade of this specific structure drives to complete ubiquitin-proteasome machinery withdrawal. Total intracellular protein flow is regulated by the proteasome activity which acts through basal and signal activated proteolysis as the result of cell stimuli. Blockade of proteasome activity contribute to cell protein hyper concentration which results with activation of cell death mechanisms. This is primary endpoint of PI activity against the cancer cell. Multiple myeloma (MM) represents the second most frequent blood cancer. The backbone of therapy constitute of triple-combination of long-acting corticosteroid (dexamethason), imunomodulatory drugs (IMiDs), such as thalidomide, lenalidomideorpomalidomide, and PI. Treatment strategy involves the use of induction therapy, after which, if disease is sensitive, high dose therapy should be followed by autologous hematopoietic stem cell transplantation. The above-mentioned treatment modality is reserved for younger patients (≤65 years), while elderly have medical treatment without transplantation. Whether maintenance therapy should be applied after remission is achieved, remains a matter of great controversy, although many centers apply it as 'off label' use. Reversible PIs include: bortezomib and ixazomib, and irreversible PI include: carfilzomib, oprozomib and marizomib. These drugs are found to have tolerable safety profile with the accent on peripheral neuropathy, gastrointestinal and moderate hematological toxicityas the most usual adverse events. This article will consider clinical pharmacology of PIs.
Keywords	proteasome ; proteasome inhibitors ; multiple myeloma ; rational therapy ; Medicine (General) ; R5-920
Subject code	610
Language	English
Publishing date	2016-01-01T00:00:00Z
Publisher	Medicinsko društvo za racionalnu terapiju Republike Srbije
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Do we really know how to overcome trastuzumab resistance in hormone sensitive metastatic breast cancer?

Cvetanovic, Ana / Pejcic, Ivica / Zivkovic, Nikola / Krtinic, Dane / Kostic, Milos / Popovic, Lazar

Journal of B.U.ON. : official journal of the Balkan Union of Oncology

2019 Volume 24, Issue 2, Page(s) 516–521

Abstract: Purpose: This article focuses on how the status of hormone receptors (HR) influences the efficacy of trastuzumab in patients with metastatic HER2-positive breast cancer treated with first-line trastuzumab in combination with taxane-based chemotherapy.!## ...

Abstract	Purpose: This article focuses on how the status of hormone receptors (HR) influences the efficacy of trastuzumab in patients with metastatic HER2-positive breast cancer treated with first-line trastuzumab in combination with taxane-based chemotherapy. Methods: A prospective study was carried out at the Clinic for Oncology, Clinical Centre in Nis, from January 2015 to until June 2018. A total of 121 patients were treated with first-line trastuzumab in combination with taxane-based chemotherapy. None of the patients from the HR-positive group received hormonotherapy after completion of chemotherapy with trastuzumab. Results: Clinical benefit rate was present in 76% of the patients, including partial response (PR) in 37%, stable disease (SD) in 38%, and complete response (CR) in almost 8% of the patients. Progressive disease (PD) occurred in almost a quarter of the patients, i.e. 24%. Progression-free survival (PFS) in the entire group of patients amounted to 9 months, whereas overall survival (OS) was 30 months. PFS in the HR-negative tumor group was significantly longer (13 months) compared to 8 months in the HR-positive tumor group (p<0.0001; HR 0.49;95% CI 0.31-0.69). Furthermore, OS was significantly longer in the HR-negative tumor group (34 months), compared to 26 months in the HR-positive tumor group (p=0.0073, HR 0.57; 95% CI 0.36-0.90). Conclusions: These data indicate a different response to anti-HER2 therapy in patients with HER2+ metastatic breast cancer (MBC) according to HR status, thus emphasizing that ER most likely represents an escape pathway for the response to anti-HER2 target therapy and vice versa. Combining hormonotherapy with anti-HER2 therapy surely represents a promising strategy which could help overcome resistance to trastuzumab and other anti-HER2 agents.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Bridged-Ring Compounds/administration & dosage ; Bridged-Ring Compounds/adverse effects ; Drug Resistance, Neoplasm/drug effects ; Female ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Staging ; Progression-Free Survival ; Prospective Studies ; Receptor, ErbB-2/genetics ; Receptors, Estrogen/genetics ; Taxoids/administration & dosage ; Taxoids/adverse effects ; Trastuzumab/administration & dosage ; Trastuzumab/adverse effects ; Treatment Outcome
Chemical Substances	Bridged-Ring Compounds ; Receptors, Estrogen ; Taxoids ; taxane (1605-68-1) ; ERBB2 protein, human (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1) ; Trastuzumab (P188ANX8CK)
Language	English
Publishing date	2019-05-21
Publishing country	Greece
Document type	Journal Article
ZDB-ID	2040386-0
ISSN	2241-6293 ; 1107-0625
ISSN (online)	2241-6293
ISSN	1107-0625
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5438: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Synchronous mantle cell lymphoma and prostate adenocarcinoma-is it just a coincidence?

Petković Ivan / Stojnev Slavica / Krstić Miljan / Pejčić Ivica / Vrbić Svetislav

Vojnosanitetski Pregled, Vol 73, Iss 11, Pp 1072-

2016 Volume 1075

Abstract: Introduction. Synchronous occurrence of lymphomas and other cancers, mostly carcinomas are well established. The most of cases describe chronic lymphocytic leukemia as the leading lymphoproliferative disease with the tendency towards secondary ... ...

Abstract	Introduction. Synchronous occurrence of lymphomas and other cancers, mostly carcinomas are well established. The most of cases describe chronic lymphocytic leukemia as the leading lymphoproliferative disease with the tendency towards secondary malignancies development. Mantle cell lymphoma (MCL) has been described in only 2 cases to co-occur with prostate adenocarcinoma (PAC). There are scarce data about the connection between MCL and urology cancers. We presented the first case of synchronous occurrence of MCL and PAC in the same patient in Serbia. Case report. A 64-year-old male initially presented with fatigue, splenomegaly, and bicytopenia. The bone marrow biopsy specimen revealed extensive infiltration with MCL. During lymphoma staging procedure prostate enlargement (57 mm) was accidentally found by multislice- computed tomography (MSCT). The serum prostate specific antigen (PSA) was elevated (52 ng/mL; normal values ≤ 4 ng/mL). Transrectal ultrasound biopsy revealed PAC. High Gleason score determined high-risk locally advanced PAC. The patient underwent treatment with chemotherapy and hormone therapy due to the existence of double malignancies. Cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) was applied for MCL, and luteinizing hormonereleasing hormone (LHRH) agonist, triptorelin, for PAC. Partial response was obtained for MCL, and stable disease for PAC. In a 1.5-year observation period the patient was still disease progression free for both of malignancies. Conclusion. This case points aut that elderly males are in need for careful observation during the staging procedure for lymphoma. The literature data suggest that MCL patients are in increased risk for urologic malignancies development. However, the etiologic connection between these two entities, except male gender and older age, remains unclear.
Keywords	lymphoma ; mantle-cell ; prostatic neoplasms ; adenocarcinoma ; diagnosis ; comorbidity ; risk assessment ; Medicine (General) ; R5-920
Subject code	610
Language	English
Publishing date	2016-01-01T00:00:00Z
Publisher	Military Health Department, Ministry of Defance, Serbia
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: New frontiers of target therapy in oncology

Petković Ivan / Pejčić Ivica / Vrbić Svetislav

Acta Facultatis Medicae Naissensis, Vol 31, Iss 1, Pp 17-

acute promyelocytic leukemia

2014 Volume 28

Abstract: Uvođenjem all-trans retinoične kiseline (ATRA) u de novo akutnoj promijelocitnoj leukemiji (APL) napravljena je revolucija u terapiji ove bolesti. Stopa molekularnih kompletnih remisija (CR) udvostručila se u odnosu na konvencionalnu hemioterapiju ... ...

Abstract	Uvođenjem all-trans retinoične kiseline (ATRA) u de novo akutnoj promijelocitnoj leukemiji (APL) napravljena je revolucija u terapiji ove bolesti. Stopa molekularnih kompletnih remisija (CR) udvostručila se u odnosu na konvencionalnu hemioterapiju antraciklinima i kreće se 90-95%. Konsolidaciona terapija je obavezna radi redukcije rizika od ranog relapsa bolesti. Terapija održavanja je preporučena jer dodatno redukuje rizik od relapsa, pogotovo kod visoko rizičnih bolesnika. Stopa relapsa APL je relativno visoka, oko 30%, i najčešća je unutar tri godine od početka lečenja. Drugi agens, arsen trioksid (ATO) je optimalni medikament koji postiže visoke stope CR u relapsu, oko 80%, a transplantacija matičnih ćelija hematopoeze (TMĆH) može produžiti ukupno preživljavanje bolesnika sa APL. ATRA i ATO su postali paradigma target terapije, a APL paradigma kurabilne maligne bolesti, bar u odnosu na druge forme akutnih mijeloidnih leukemija (AML).
Keywords	acute promyelocytic leukemia ; target therapy ; akutna promijelocitna leukemija ; ciljana terapija ; Medicine ; R
Language	English
Publishing date	2014-03-01T00:00:00Z
Publisher	Sciendo
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Survival of patients with liver metastases from colorectal cancer treated with bevacizumab and FOLFOX4.

Dzunic, Miljana / Andjelkovic-Apostolovic, Marija / Vrbic, Svetislav / Pejcic, Ivica / Petkovic, Ivan / Cvetanovic, Ana / Dinic, Sasa

Journal of B.U.ON. : official journal of the Balkan Union of Oncology

2020 Volume 25, Issue 1, Page(s) 212–219

MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bevacizumab/pharmacology ; Bevacizumab/therapeutic use ; Colorectal Neoplasms/complications ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/mortality ; Colorectal Neoplasms/pathology ; Female ; Fluorouracil/pharmacology ; Fluorouracil/therapeutic use ; Humans ; Leucovorin/pharmacology ; Leucovorin/therapeutic use ; Liver Neoplasms/drug therapy ; Liver Neoplasms/mortality ; Liver Neoplasms/pathology ; Liver Neoplasms/secondary ; Male ; Middle Aged ; Neoplasm Metastasis ; Organoplatinum Compounds/pharmacology ; Organoplatinum Compounds/therapeutic use ; Survival Analysis ; Treatment Outcome
Chemical Substances	Organoplatinum Compounds ; Bevacizumab (2S9ZZM9Q9V) ; Leucovorin (Q573I9DVLP) ; Fluorouracil (U3P01618RT)
Language	English
Publishing date	2020-04-10
Publishing country	Greece
Document type	Journal Article
ZDB-ID	2040386-0
ISSN	2241-6293 ; 1107-0625
ISSN (online)	2241-6293
ISSN	1107-0625
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5438: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Significance of Echocardiography in the Assessment of Left Ventricular Function in Patients Receiving Combined Adjuvant Treatment with Anthracyclines and Trastuzumab / Značaj ehokardiografije u proceni funkcije leve komore kod bolesnica na adjuvantnoj terapji (kombinovana terapija antraciklinima i trastuzumabom)

Krstić Ivana / Ilić Marina Deljanin / Vrbić Svetislav / Pejčić Ivica

Acta Facultatis Medicae Naissensis, Vol 32, Iss 3, Pp 181-

2015 Volume 187

Abstract: Primena antraciklina i trastuzumaba u adjuvantnom pristupu lečenja karcinoma dojke je značajno poboljšala preživljavanje ovih bolesnica, ali nosi rizik od kardiotoksičnosti koja se manifestuje smanjenjem ejekcione frakcije srca. ...

Abstract	Primena antraciklina i trastuzumaba u adjuvantnom pristupu lečenja karcinoma dojke je značajno poboljšala preživljavanje ovih bolesnica, ali nosi rizik od kardiotoksičnosti koja se manifestuje smanjenjem ejekcione frakcije srca.
Keywords	ejection fraction ; anthracyclines ; trastuzumab ; ejekciona frakcija ; antraciklini ; Medicine ; R
Language	English
Publishing date	2015-09-01T00:00:00Z
Publisher	De Gruyter Open
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Application of anti-CD20 monoclonal antibodies in the treatment of lymphoproliferative diseases

Pejčić Ivica / Vrbić Svetislav

Archive of Oncology, Vol 17, Iss 3-4, Pp 65-

2009 Volume 67

Abstract: Out of numerous studied monoclonal antibodies, only a few reached the stage of clinical application. The CD20 molecule, non-glycolysed phospholipoprotein (usually termed B1), belonging to the tetraspan (TM4SF) family, 35-37 kD, is characteristic for all ... ...

Abstract	Out of numerous studied monoclonal antibodies, only a few reached the stage of clinical application. The CD20 molecule, non-glycolysed phospholipoprotein (usually termed B1), belonging to the tetraspan (TM4SF) family, 35-37 kD, is characteristic for all mature B lymphocytes, including CLL cells. The CD20 receptors, characteristic for 'B' lymphoproliferative diseases, have been demonstrated to be a good target for therapeutic effects to be achieved. Rituximab is a chimeric anti-CD20 IgG1 monoclonal antibody, with the sequences of the human constant region and sequences of the murine variable region. It is specifically bound to the B-lymphocyte CD20 antigen. The mechanism of all rituximab antitumor activity has not been established, but ADCC and CDC are believed to be the principal, with possible complementary effects. Therapeutic use of anti-CD20 monoclonal antibodies has demonstrated a significant benefit in the patients with 'B' CD20 positive lymphoproliferative diseases. Rituximab is today a golden standard for the comparation with other treatment modalities, increasingly in combination with chemotherapy.
Keywords	Lymphoproliferative Disorders ; Antibodies ; Monoclonal ; Antigens ; CD20 ; Neoplasms. Tumors. Oncology. Including cancer and carcinogens ; RC254-282 ; Internal medicine ; RC31-1245 ; Medicine ; R ; DOAJ:Oncology ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
Subject code	616
Language	English
Publishing date	2009-01-01T00:00:00Z
Publisher	Institute of Oncology Sremska Kamenica
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

Full text online

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED